Skip to main content
MetaVia Inc. logo

MetaVia Inc. — Investor Relations & Filings

Ticker · MTVA ISIN · US64132R1077 US Manufacturing
Filings indexed 601 across all filing types
Latest filing 2026-05-18 Regulatory Filings
Country US United States of America
Listing US MTVA

About MetaVia Inc.

https://metaviatx.com/

MetaVia Inc. is a clinical-stage biotechnology company focused on developing novel pharmaceuticals for cardiometabolic diseases. The company's pipeline is centered on innovative treatments for obesity and metabolic dysfunction-associated steatohepatitis (MASH). Its lead product candidate, DA-1726, is a dual oxyntomodulin (OXM) analog agonist that functions on both the glucagon-like peptide-1 receptor (GLP1R) and the glucagon receptor (GCGR), under development for obesity. Another key asset is Vanoglipel, a G-Protein-Coupled Receptor 119 (GPR119) agonist being developed for MASH.

Recent filings

Filing Released Lang Actions
8-K
Regulatory Filings
2026-05-18 English
10-Q
Interim / Quarterly Report
2026-05-14 English
8-K
Regulatory Filings
2026-05-14 English
8-K - MetaVia Inc. (0001638287) (Filer)
Regulatory Filings
2026-05-11 English
ARS - MetaVia Inc. (0001638287) (Filer)
Annual Report
2026-04-27 English
DEF 14A - MetaVia Inc. (0001638287) (Filer)
Proxy Solicitation & Information Statement
2026-04-27 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.